chloroquine has been researched along with Burkitt Lymphoma in 13 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Burkitt Lymphoma: A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here we show that chloroquine, a drug that activates the stress-responsive Atm-p53 tumor-suppressor pathway, preferentially enhances the death of Myc oncogene-overexpressing primary mouse B cells and mouse embryonic fibroblasts (MEFs) and impairs Myc-induced lymphomagenesis in a transgenic mouse model of human Burkitt lymphoma." | 3.74 | Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. ( Cleveland, JL; Dorsey, FC; Kastan, MB; Maclean, KH, 2008) |
| "The immunotoxin bound to all Burkitt's lymphoma cell lines that were tested but not to human peripheral blood T cells." | 1.27 | Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. ( Houston, LL; Ramakrishnan, S; Uckun, FM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (61.54) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Burton, EM | 1 |
| Bhaduri-McIntosh, S | 1 |
| Dang, CV | 1 |
| Maclean, KH | 1 |
| Dorsey, FC | 1 |
| Cleveland, JL | 1 |
| Kastan, MB | 1 |
| Branca, AA | 1 |
| Faltynek, CR | 1 |
| D'Alessandro, SB | 1 |
| Baglioni, C | 1 |
| Vervoordeldonk, SF | 1 |
| Balkenende, AY | 1 |
| van den Berg, H | 1 |
| von dem Borne, AE | 1 |
| van der Schoot, CE | 1 |
| Van Leeuwen, EF | 1 |
| Slaper-Cortenbach, IC | 1 |
| Van Horssen, PJ | 1 |
| Preijers, FW | 1 |
| Van Oosterhout, YV | 1 |
| Eling, WM | 1 |
| De Witte, T | 1 |
| Karmali, RA | 1 |
| Horrobin, DF | 1 |
| Menezes, J | 1 |
| Patel, P | 1 |
| Musto, J | 1 |
| Lenoir, G | 1 |
| Geser, A | 3 |
| Brubaker, G | 2 |
| Draper, CC | 1 |
| Uckun, FM | 1 |
| Ramakrishnan, S | 1 |
| Houston, LL | 1 |
| Bruce-Chwatt, LJ | 1 |
| Bedoya, V | 1 |
13 other studies available for chloroquine and Burkitt Lymphoma
| Article | Year |
|---|---|
Chloroquine triggers Epstein-Barr virus replication through phosphorylation of KAP1/TRIM28 in Burkitt lymphoma cells.
Topics: Antimalarials; Ataxia Telangiectasia Mutated Proteins; Burkitt Lymphoma; Cell Line, Tumor; Chloroqui | 2017 |
Antimalarial therapy prevents Myc-induced lymphoma.
Topics: Animals; Antimalarials; Apoptosis; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Au | 2008 |
Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis.
Topics: Animals; Antirheumatic Agents; Apoptosis; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Prote | 2008 |
Interaction of interferon with cellular receptors. Internalization and degradation of cell-bound interferon.
Topics: Biological Transport; Burkitt Lymphoma; Cell Line; Chloroquine; Colchicine; Cytochalasin D; Cytochal | 1982 |
Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCgamma-receptor-II-mediated mechanism and by drugs.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Antigens, CD19; Antigens, Differentiation, B-Lymphocy | 1996 |
Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
Topics: Animals; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Burkitt Lymph | 2000 |
Chloroquine enhances Epstein-Barr virus expression.
Topics: Antigens, Viral; Burkitt Lymphoma; Cell Line; Chloroquine; Herpesvirus 4, Human; Virus Replication | 1978 |
Effect of chloroquine on Epstein-Barr virus expression.
Topics: Antigens, Viral; Burkitt Lymphoma; Cells, Cultured; Chloroquine; Herpesvirus 4, Human; Humans; Malar | 1979 |
Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma.
Topics: Adolescent; Age Factors; Burkitt Lymphoma; Child; Child, Preschool; Chloroquine; Female; Humans; Inf | 1989 |
A preliminary report of epidemiological studies of Burkitt's lymphoma, Epstein-Barr virus infection and malaria in North Mara, Tanzania.
Topics: Adolescent; Age Factors; Antibodies, Viral; Burkitt Lymphoma; Child; Child, Preschool; Chloroquine; | 1985 |
Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; Binding Sites, Antibody; Bone Marrow; Bone | 1985 |
Letter: Antimalarial drugs and Burkitt's lymphoma.
Topics: Adult; Africa; Animals; Burkitt Lymphoma; Carcinogens; Child; Chloroquine; Humans; Plant Extracts; P | 1974 |
Effect of chloroquine on malignant lymphoreticular and pigmented cells in vitro.
Topics: Animals; Burkitt Lymphoma; Cell Nucleolus; Cell Nucleus; Chloroquine; Culture Techniques; Cytoplasm; | 1970 |